Lysophosphatidic acid mediates the rapid activation of platelets and endothelial cells by mildly oxidized low density lipoprotein and accumulates in human atherosclerotic lesions
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
Oxidized low density lipoprotein (LDL) is a key factor in the pathogenesis of atherosclerosis and its thrombotic complications, such as stroke and myocardial infarction. It activates endothelial cells and platelets through mechanisms that are largely unknown. Here, we show that lysophosphatidic acid (LPA) was formed during mild oxidation of LDL and was the active compound in mildly oxidized LDL and minimally modified LDL, initiating platelet activation and stimulating endothelial cell stress-fiber and gap formation. Antagonists of the LPA receptor prevented platelet and endothelial cell activation by mildly oxidized LDL. We also found that LPA accumulated in and was the primary platelet-activating lipid of atherosclerotic plaques. Notably, the amount of LPA within the human carotid atherosclerotic lesion was highest in the lipid-rich core, the region most thrombogenic and most prone to rupture. Given the potent biological activity of LPA on platelets and on cells of the vessel wall, our study identifies LPA as an atherothrombogenic molecule and suggests a possible strategy to prevent and treat atherosclerosis and cardiocerebrovascular diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Phosphorus Assay in Column Chromatography
Bartlett, G. R. (1959) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)70226-3 · Cited by 12,801
The pathogenesis of atherosclerosis: a perspective for the 1990s
Ross, R. (1993) · Nature · doi:10.1038/362801a0 · Cited by 10,630
Falk, E., Shah, P. K., & Fuster, V. (1995) · Circulation · doi:10.1161/01.cir.92.3.657 · Cited by 3,536
Atherosclerosis: Basic Mechanisms: Oxidation, Inflammation, and Genetics
Berliner, J. A., Navab, M., Fogelman, A. M., Frank, J. S., Demer, L. L., Edwards, P. A., Watson, A. D., & Lusis, A. J. (1995) · Circulation · doi:10.1161/01.cir.91.9.2488 · Cited by 1,701
Minimally modified low density lipoprotein stimulates monocyte endothelial interactions.
Berliner, J. A., Territo, M. C., Sevanian, A., Ramin, S., Kim, J. A., Bamshad, B., Esterson, M., & Fogelman, A. M. (1990) · Journal of Clinical Investigation · doi:10.1172/jci114562 · Cited by 925
Molecular mechanisms of platelet activation.
Siess, W. (1989) · Physiological Reviews · doi:10.1152/physrev.1989.69.1.58 · Cited by 881
Self-citationLewis A. Conner Memorial Lecture: Oxidative Modification of LDL and Atherogenesis
Steinberg, D. (1997) · Circulation · doi:10.1161/01.cir.95.4.1062 · Cited by 748
The bioactive phospholipid lysophosphatidic acid is released from activated platelets
Eichholtz, T., Jalink, K., Fahrenfort, I., & Moolenaar, W. H. (1993) · Biochemical Journal · doi:10.1042/bj2910677 · Cited by 645
Fernández-Ortiz, A., Badimon, J. J., Falk, E., Fuster, V., Meyer, B., Mailhac, A., Weng, D., Shah, P. K., & Badimon, L. (1994) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(94)90657-2 · Cited by 587
Lysophosphatidic Acid, a Multifunctional Phospholipid Messenger
Moolenaar, W. H. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.22.12949 · Cited by 584
Cited by
Atherosclerosis: current pathogenesis and therapeutic options
Weber, C., & Noels, H. (2011) · Nature Medicine · doi:10.1038/nm.2538 · Cited by 2,203
The emerging role of lysophosphatidic acid in cancer
Mills, G. B., & Moolenaar, W. H. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1143 · Cited by 1,094
LPA Receptors: Subtypes and Biological Actions
Choi, J. W., Herr, D. R., Noguchi, K., Yung, Y. C., Lee, C.-W., Mutoh, T., Lin, M.-E., Teo, S. T., Park, K. E., Mosley, A. N., et al. (2010) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.010909.105753 · Cited by 839
LPA receptor signaling: pharmacology, physiology, and pathophysiology
Yung, Y. C., Stoddard, N. C., & Chun, J. (2014) · Journal of Lipid Research · doi:10.1194/jlr.r046458 · Cited by 710
Arterial thrombosis—insidious, unpredictable and deadly
Jackson, S. P. (2011) · Nature Medicine · doi:10.1038/nm.2515 · Cited by 685
The ins and outs of lysophosphatidic acid signaling
Moolenaar, W. H., van Meeteren, L. A., & Giepmans, B. N. G. (2004) · BioEssays · doi:10.1002/bies.20081 · Cited by 571
McIntyre, T. M., Pontsler, A. V., Silva, A. R., St. Hilaire, A., Xu, Y., Hinshaw, J. C., Zimmerman, G. A., Hama, K., Aoki, J., Arai, H., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0135855100 · Cited by 550
Oxidized LDL: Diversity, Patterns of Recognition, and Pathophysiology
Levitan, I., Volkov, S., & Subbaiah, P. V. (2010) · Antioxidants & Redox Signaling · doi:10.1089/ars.2009.2733 · Cited by 473
Molecular Biology of Atherosclerosis
Hopkins, P. N. (2013) · Physiological Reviews · doi:10.1152/physrev.00004.2012 · Cited by 459
Role of Monocytes in Atherogenesis
ØSTERUD, B., & BJØRKLID, E. (2003) · Physiological Reviews · doi:10.1152/physrev.00005.2003 · Cited by 412
Murata, N., Sato, K., Kon, J., Tomura, H., YANAGITA, M., Kuwabara, A., Ui, M., & Okajima, F. (2000) · Biochemical Journal · doi:10.1042/0264-6021:3520809 · Cited by 407
Bioactive Lysophospholipids and Their G Protein-Coupled Receptors
Moolenaar, W. H. (1999) · Experimental Cell Research · doi:10.1006/excr.1999.4702 · Cited by 407
Ki16425, a Subtype-Selective Antagonist for EDG-Family Lysophosphatidic Acid Receptors
Ohta, H., Sato, K., Murata, N., Damirin, A., Malchinkhuu, E., Kon, J., Kimura, T., Tobo, M., Yamazaki, Y., Watanabe, T., et al. (2003) · Molecular Pharmacology · doi:10.1124/mol.64.4.994 · Cited by 402
Lysophosphatidic acid (LPA) receptors: Signaling properties and disease relevance
Lin, M.-E., Herr, D. R., & Chun, J. (2010) · Prostaglandins & Other Lipid Mediators · doi:10.1016/j.prostaglandins.2009.02.002 · Cited by 363
Oxidized low-density lipoprotein-induced apoptosis
Salvayre, R., Auge, N., Benoist, H., & Negre-Salvayre, A. (2002) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/s1388-1981(02)00343-8 · Cited by 330
Fukushima, N., Ishii, I., Contos, J. J., Weiner, J. A., & Chun, J. (2001) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.41.1.507 · Cited by 322
Hirase, T., Kawashima, S., Wong, E. Y. M., Ueyama, T., Rikitake, Y., Tsukita, S., Yokoyama, M., & Staddon, J. M. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m007136200 · Cited by 311
Westein, E., van der Meer, A. D., Kuijpers, M. J. E., Frimat, J.-P., van den Berg, A., & Heemskerk, J. W. M. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1209905110 · Cited by 304
Hundelshausen, P. V., & Lievens, D. (2011) · Thrombosis and Haemostasis · doi:10.1160/th11-08-0592 · Cited by 271
Kimura, T., Sato, K., Kuwabara, A., Tomura, H., Ishiwara, M., Kobayashi, I., Ui, M., & Okajima, F. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m104353200 · Cited by 261
Chen, K., Febbraio, M., Li, W., & Silverstein, R. L. (2008) · Circulation Research · doi:10.1161/circresaha.108.172064 · Cited by 202
MALCHINKHUU, E., SATO, K., MURAKI, T., ISHIKAWA, K., KUWABARA, A., & OKAJIMA, F. (2003) · Biochemical Journal · doi:10.1042/bj20020867 · Cited by 45
Metadata
- Authors
- Siess, W., Zangl, K. J., Essler, M., Bauer, M., Brandl, R., Corrinth, C., Bittman, R., Tigyi, G., & Aepfelbacher, M.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 1999-06-08
- Volume
- 96
- Issue
- 12
- Pages
- 6931-6936
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2141583613
- Cited by
- 404
- References
- 29
- FWCI
- 7.37
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.